MARKET

IPHYF

IPHYF

Innate Pharma Marseille
OTCPK
1.990
NaN%
Opening 09:30 12/05 EST
OPEN
--
PREV CLOSE
1.990
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
1.350
MARKET CAP
183.39M
P/E (TTM)
-3.0767
1D
5D
1M
3M
1Y
5Y
1D
Innate Pharma Releases Share and Voting Rights Update as of November 27, 2025
TipRanks · 11/28 14:27
Innate Pharma Presents at Jefferies Global Healthcare Conference 2025
TipRanks · 11/17 11:30
Innate Pharma’s Q3 2025 Update: FDA Clears Phase 3 Trial for Lacutamab
TipRanks · 11/13 11:38
Innate Pharma Receives FDA Clearance for Phase 3 Lacutamab Trial
TipRanks · 11/10 11:48
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
TipRanks · 11/10 11:00
Innate Pharma Schedules Q3 2025 Results Conference Call
TipRanks · 11/05 11:27
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
TipRanks · 10/29 10:10
Innate Pharma’s IPH4502: A Promising Step in Cancer Treatment
TipRanks · 10/27 19:15
More
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA stock information, including OTCPK: IPHYF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHYF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHYF stock methods without spending real money on the virtual paper trading platform.